Abstract
Nipah virus (NiV) continues to remain a significant threat to health of the public, characterized by its ability to cause respiratory and neurological complications. The World Health Organization (WHO) has identified NiV as a priority disease for its R and D Blueprint. However, despite extensive research efforts, specific antiviral therapies for NiV infection are currently unavailable. This highlights the crucial need to focus on supportive care for patients affected by the NiV. Therapies Prompt medical attention, including mechanical ventilation and intensive care, is crucial in case of NiV infection. Preventive measures such as avoiding consumption of raw date palm sap and implementing control of infection practices, gives a major role in halting the spread of NiV. This review provides a comprehensive overview of NiV, including its unique characteristics, clinical manifestations, diagnostic methods, treatment strategies, and preventive measures. The article also provides details on vaccines currently undergoing clinical trials, including ChAdOx1, PHV02, mRNA-1215, HeV-sG-V, and CD40.NiV. In addition, it highlights that the m102.4 monoclonal antibody and nucleotide analogue remdesivir has shown effective in the Non-Human Primate (NHP) model was also reviewed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
